Business - Briefly   

DRL settles legal issues with U.K. companies

HYDERABAD: Dr. Reddy’s Laboratories (DRL) has entered into agreements with the U.K.-based pharma companies, Schering and Sepracor, which would allow DRL to manufacture and market generic versions of the Clarinex-D-12 hour and Clarinex-D-24 hour products, with six months marketing exclusivity, according to a release. The agreements resolved all pending patent infringement actions filed by Schering and Sepracor against DRL in the U.S. District Court for the District of New Jersey. — Special Correspondent

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Lifetime achievement award for RP Goenka
Global meltdown: moderate impact on manufacturing seen
Reliance Infra sole bidder for expressway
India, China make steady progress in real estate transparency levels
Tilaiya UMPP getting delayed
Maruti may cut production if slowdown continues
Sensex surrenders 118 points on profit booking
GE to sell Australian mortgage business
Wachovia, Wells Fargo merger gets nod
Toyota to raise Innova, Altis prices
China plans trade settlement in yuan
Finance panels’ role undermined: study
SBT not affected by economic slump, says Managing Director
Exchange Rates
Bullion Rates
DRL settles legal issues with U.K. companies
Fortis Healthcare plans rights issue
Nuance solution for organising documents
GlobalOutlook offers Saas, host exchange
Car portal with interactive animations
Indian Bank sets up cell for pensioners

Copyright © 2008, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu